The University of Chicago Header Logo

Connection

Peter Sand to Male

Back to Details
This is a "connection" page, showing publications Peter Sand has written about Male.
Peter Sand
Connection Strength
0.462
Male
  1. Twelve-month Durability of a Fully-implanted, Nickel-sized and Shaped Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome with Urgency Urinary Incontinence: A Single-Arm, Prospective Study. Urology. 2021 11; 157:71-78.
    View in: PubMed
    Score: 0.039
  2. The diagnosis and management of lower urinary tract symptoms in multiple sclerosis patients. Dis Mon. 2013 Jul; 59(7):261-8.
    View in: PubMed
    Score: 0.023
  3. The reliability and validity of the revised Diabetes Family Conflict Scale questionnaire, in a sample of Swedish children. Acta Paediatr. 2013 Jun; 102(6):650-4.
    View in: PubMed
    Score: 0.022
  4. The reliability of the Health Related Quality Of Life questionnaire PedsQL 3.0 Diabetes Module™ for Swedish children with type 1 diabetes. Acta Paediatr. 2012 Aug; 101(8):e344-9.
    View in: PubMed
    Score: 0.021
  5. Long-term safety, tolerability and efficacy of fesoterodine in subjects with overactive bladder symptoms stratified by age: pooled analysis of two open-label extension studies. Drugs Aging. 2012 Feb 01; 29(2):119-31.
    View in: PubMed
    Score: 0.020
  6. Once-daily trospium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: Post hoc analysis of pooled data from two randomized, placebo-controlled trials. Drugs Aging. 2011 Feb 01; 28(2):151-60.
    View in: PubMed
    Score: 0.019
  7. Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged = 75 years) with overactive bladder syndrome. BJU Int. 2011 Feb; 107(4):612-20.
    View in: PubMed
    Score: 0.018
  8. Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement? BJU Int. 2010 Sep; 106(6):816-21.
    View in: PubMed
    Score: 0.018
  9. Extended-release trospium chloride improves quality of life in overactive bladder. Value Health. 2010 Mar-Apr; 13(2):251-7.
    View in: PubMed
    Score: 0.017
  10. Patient-reported most bothersome symptoms in OAB: post hoc analysis of data from a large, open-label trial of solifenacin. Int Urogynecol J Pelvic Floor Dysfunct. 2009 Jun; 20(6):667-75.
    View in: PubMed
    Score: 0.017
  11. Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study. Pharmacoeconomics. 2009; 27(4):329-39.
    View in: PubMed
    Score: 0.017
  12. Association between response to pentosan polysulfate sodium therapy for interstitial cystitis and patient questionnaire-based treatment satisfaction. Curr Med Res Opin. 2008 Aug; 24(8):2259-64.
    View in: PubMed
    Score: 0.016
  13. Time to initiation of pentosan polysulfate sodium treatment after interstitial cystitis diagnosis: effect on symptom improvement. Urology. 2008 Jan; 71(1):57-61.
    View in: PubMed
    Score: 0.015
  14. Botulinum toxin A in the overactive bladder: current status and future directions. BJU Int. 2007 Feb; 99(2):247-62.
    View in: PubMed
    Score: 0.014
  15. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int. 2007 Apr; 99(4):836-44.
    View in: PubMed
    Score: 0.014
  16. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. Am J Obstet Gynecol. 2006 Dec; 195(6):1730-5.
    View in: PubMed
    Score: 0.014
  17. Children Treated for Nonsyndromic Craniosynostosis Exhibit Average Adaptive Behavior Skills with Only Minor Shortcomings. Plast Reconstr Surg. 2021 02 01; 147(2):453-464.
    View in: PubMed
    Score: 0.010
  18. Evaluation of a new once-daily formulation of oxbutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group. Urology. 1999 Sep; 54(3):420-3.
    View in: PubMed
    Score: 0.009
  19. A Prospective Study to Evaluate Efficacy Using the Nuro Percutaneous Tibial Neuromodulation System in Drug-Naïve Patients With Overactive Bladder Syndrome. Urology. 2019 Sep; 131:77-82.
    View in: PubMed
    Score: 0.009
  20. The Cognitive Profile of Children with Nonsyndromic Craniosynostosis. Plast Reconstr Surg. 2019 05; 143(5):1037e-1052e.
    View in: PubMed
    Score: 0.008
  21. Feasibility of a Fully Implanted, Nickel Sized and Shaped Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome with Urgency Urinary Incontinence. J Urol. 2019 05; 201(5):967-972.
    View in: PubMed
    Score: 0.008
  22. The evaluation and management of hematuria in women. Int Urogynecol J Pelvic Floor Dysfunct. 1997; 8(3):156-60.
    View in: PubMed
    Score: 0.007
  23. OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial. J Urol. 2017 02; 197(2S):S216-S223.
    View in: PubMed
    Score: 0.007
  24. Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study. J Urol. 2016 Sep; 196(3):791-800.
    View in: PubMed
    Score: 0.007
  25. Health-related quality of life in preschool children with Type 1 diabetes. Diabet Med. 2015 Jan; 32(1):116-9.
    View in: PubMed
    Score: 0.006
  26. Efficacy and safety of oxybutynin topical gel 3% in patients with urgency and/or mixed urinary incontinence: a randomized, double-blind, placebo-controlled study. Neurourol Urodyn. 2015 Jan; 34(1):37-43.
    View in: PubMed
    Score: 0.006
  27. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013 Jun; 189(6):2186-93.
    View in: PubMed
    Score: 0.005
  28. Treatment satisfaction and goal attainment with onabotulinumtoxinA in patients with incontinence due to idiopathic OAB. Int Urogynecol J. 2012 Aug; 23(8):1017-25.
    View in: PubMed
    Score: 0.005
  29. Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms. Neurourol Urodyn. 2011 Sep; 30(7):1214-9.
    View in: PubMed
    Score: 0.005
  30. Long-term safety, tolerability, and efficacy of fesoterodine treatment in men and women with overactive bladder symptoms. Curr Med Res Opin. 2011 May; 27(5):921-30.
    View in: PubMed
    Score: 0.005
  31. Executive Summary: The International Consultation on Incontinence 2008--Committee on: "Dynamic Testing"; for urinary or fecal incontinence. Part 3: Anorectal physiology studies. Neurourol Urodyn. 2010; 29(1):153-8.
    View in: PubMed
    Score: 0.004
  32. Executive summary: The International Consultation on Incontinence 2008--Committee on: "Dynamic Testing"; for urinary or fecal incontinence. Part 2: Urodynamic testing in male patients with symptoms of urinary incontinence, in patients with relevant neurological abnormalities, and in children and in frail elderly with symptoms of urinary incontinence. Neurourol Urodyn. 2010; 29(1):146-52.
    View in: PubMed
    Score: 0.004
  33. Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials. Int J Clin Pract. 2009 Dec; 63(12):1715-23.
    View in: PubMed
    Score: 0.004
  34. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol. 2009 Apr; 181(4):1764-72.
    View in: PubMed
    Score: 0.004
  35. Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology. 2008 Mar; 71(3):449-54.
    View in: PubMed
    Score: 0.004
  36. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol. 2007 Dec; 178(6):2488-94.
    View in: PubMed
    Score: 0.004
  37. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. J Urol. 2007 Sep; 178(3 Pt 1):978-83; discussion 983-4.
    View in: PubMed
    Score: 0.004
  38. Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials. Int Urol Nephrol. 2007; 39(4):1069-77.
    View in: PubMed
    Score: 0.004
  39. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Clin Ther. 2006 Nov; 28(11):1935-46.
    View in: PubMed
    Score: 0.004
  40. Evaluation of male consorts of women with genital human papilloma virus infection. Obstet Gynecol. 1986 Nov; 68(5):679-81.
    View in: PubMed
    Score: 0.004
  41. Voiding dysfunction in the adolescent. Obstet Gynecol Surv. 1986 Jun; 41(6):342-7.
    View in: PubMed
    Score: 0.003
  42. Cholecystokinin- and cholecystokinin-B-receptor gene polymorphisms in panic disorder. J Neural Transm Suppl. 2004; (68):147-56.
    View in: PubMed
    Score: 0.003
  43. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology. 2003 Aug; 62(2):237-42.
    View in: PubMed
    Score: 0.003
  44. Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: a one-year study. Int Urol Nephrol. 2002; 34(1):43-9.
    View in: PubMed
    Score: 0.003
  45. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc. 2001 Apr; 76(4):358-63.
    View in: PubMed
    Score: 0.002
  46. [Signs of inflammation and hemorrhage in the rectal mucosa during therapy of rectal constipation with phosphate enemata and bisacodyl rectal tube]. Ugeskr Laeger. 1978 Aug 21; 140(34):2041-4.
    View in: PubMed
    Score: 0.002
  47. Psychopathological and neuropsychological effects of 8-days' corticosteroid treatment. A prospective study. Psychoneuroendocrinology. 1996 Jan; 21(1):25-31.
    View in: PubMed
    Score: 0.002
  48. [Alcohol and drug abuse as risk factors for violence and delinquency in schizophrenic patients]. Psychiatr Prax. 1993 Sep; 20(5):172-5.
    View in: PubMed
    Score: 0.001
  49. Pregnancy outcome subsequent to consecutive hydatidiform moles. Am J Obstet Gynecol. 1982 Apr 15; 142(8):1060-1.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.